Neurofilament-light chain (NfL) and glial fibrillary acidic protein (GFAP) are two of the main fluid biomarkers currently being examined for their clinical utility in evaluating disease activity, progression and treatment response. However, there are a number of other biomarkers under investigation. The following is a summary of some of the more promising candidates (reviewed in Maroto-Garcia et al. Clin Chim Acta 2023;548:117471). Read More
Neurology
sNfL a useful alternative to gadolinium
July 31, 2023The prospective REDUCE-GAD study reports that higher serum neurofilament-light chain (NfL) levels are associated with the presence of contrast-enhancing (CE) lesions, which may enable clinicians to forego contrast agents for follow-up MRIs (Schaefer et al. Eur J Neurol 2023;30:2393-2400). Read More
Revised recommendations on the differential diagnosis of MS
July 25, 2023The Multiple Sclerosis Differential Diagnosis Consortium has published consensus recommendations on the differential diagnosis of multiple sclerosis (Solomon et al. Lancet Neurol 2023;22:750-768). This version updates recommendations published 15 years ago (Miller et al. Mult Scler 2008;14:1157-1174). Read More
Lower risk of Gd+ lesions, new T2 lesions in older MS patients
July 18, 2023Relapse-onset MS patients have a substantially reduced risk of contrast-enhancing lesions or new T2 lesions after they reach age 50 years, according to a longitudinal analysis of the Amsterdam MS cohort study (Coerver et al. Eur J Neurol 2023;30:2385-2392). Read More
EAN HIGHLIGHTS 2023 – WEDNESDAY, JULY 5 EDITION
July 5, 2023Selected highlights from the European Academy of Neurology annual meeting, Budapest, Hungary, July 1-4, 2023.
Ofatumumab – 5-year efficacy data
MS influenced by prior pregnancies
NfL not useful to predict cognitive impairment
Improved outcome with autoimmune comorbidity in MS
Clinical tip of the day Read More